Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation.
Zondlo
Susan Carr
SC
Cardiovascular Department, Bristol-Myers Squibb Company, Experimental Station, Bldg. 400/3352, Route 141 and Henry Clay Road, 19880, Wilmington, DE, USA.
Wang
Xinkang
X
Feuerstein
Giora Z
GZ
D000284:Administration, Oral; D000409:Alanine / Q000494:pharmacology; D000578:Amidines / Q000494:pharmacology; D023201:CD40 Ligand / Q000187:drug effects / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D007962:Leukocytes / Q000166:cytology / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011506:Proteins / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D018179:Receptors, Thrombin
D000578:Amidines; D007555:Isoxazoles; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011506:Proteins; D011759:Pyrrolidines; D018179:Receptors, Thrombin; D023201:CD40 Ligand; C120234:orbofiban; D000409:Alanine; C118235:roxifiban